TY - JOUR T1 - Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports JF - Anticancer Research JO - Anticancer Res SP - 4545 LP - 4549 VL - 35 IS - 8 AU - TOSHIO INUI AU - KENTARO KUBO AU - DAISUKE KUCHIIKE AU - YOSHIHIRO UTO AU - TAKAHITO NISHIKATA AU - NORIHIRO SAKAMOTO AU - MARTIN METTE Y1 - 2015/08/01 UR - http://ar.iiarjournals.org/content/35/8/4545.abstract N2 - Background: Gc protein-derived macrophage-activating factor (GcMAF) immunotherapy has been steadily advancing over the last two decades. Oral colostrum macrophage-activating factor (MAF) produced from bovine colostrum has shown high macrophage phagocytic activity. GcMAF-based immunotherapy has a wide application for use in treating many diseases via macrophage activation or for use as supportive therapy. Results: Three case studies demonstrate that oral colostrum MAF can be used for serious infection and chronic fatigue syndrome (CFS) without adverse effects. Conclusion: We demonstrate that colostrum MAF shows promising clinical results in patients with infectious diseases and for symptoms of fatigue, which is common in many chronic diseases. ER -